Opendata, web and dolomites

BRAINSPECT

Ultra high resolution Single Photon Computed Emission Tomography for the molecular imaging of brain disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BRAINSPECT project word cloud

Explore the words cloud of the BRAINSPECT project. It provides you a very rough idea of what is the project "BRAINSPECT" about.

single    unprecedented    tomography    time    stage    patient    shorter    bandwidth    progression    indications    perfusion    modality    detection    stages    amongst    consuming    clinicians    instrument    neurotransmitter    disorders    spatial    spect    isolate    compensates    sme    sound    measuring    computed    brain    35    multibillion    movement    disease    scan    proprietary    accurate    disrupt    photon    characterising    radically    emission    uses    strategy    small    point    artefacts    images    diagnosed    complete    either    insufficient    molecular    multiple    patients    hallmarks    utility    prototype    sensitive    yield    reposition    resolution    flow    disturbed    rcbf    initial    route    plaques    cerebral    enthusiasm    lower    feasibility    resolutions    parts    clinical    proven    validation    imbalance    radiation    mentioned    worldwide    market    ring    blood    times    figure    dose    costly    commercial    sparked    regional    mi    imaging    animals    techniques    ultra    pinholes    software    fold    assessing    milabs    reconstruction   

Project "BRAINSPECT" data sheet

The following table provides information about the project.

Coordinator
MILABS BV 

Organization address
address: Heidelberglaan 100 STR. 4.105
city: Utrecht
postcode: 3584 CX
website: www.milabs.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.milabs.com/g-spect/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MILABS BV NL (Utrecht) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

MILabs’ radically new proprietary approaches for ultra-high resolution and ultra-sensitive brain SPECT (Single Photon Emission Computed Tomography) enable the measuring of disturbed regional cerebral blood flow (rCBF) perfusion, and characterising plaques and neurotransmitter imbalance - all important hallmarks of brain disorders - at unprecedented spatial resolutions. This new approach has the potential to disrupt the complete field of molecular imaging (MI), a multibillion market worldwide. Current techniques can only measure the mentioned effects in the brain either at late stages of disease progression (at which point the patients have already been diagnosed) or at insufficient resolution to isolate processes in small parts of the brain. Current SPECT results in low resolution images, are highly sensitive to patient movement and are time consuming and costly. MILabs has developed a clinical SPECT prototype, G-SPECT, which has proven its potential to reposition SPECT as the major clinical MI modality. G-SPECT uses a high bandwidth photon detection ring with multiple pinholes, and advanced reconstruction software that compensates for patient movement artefacts. This enables 35-fold higher resolution images, more accurate imaging and lower radiation dose due to shorter scan times (Figure 1). The application of MILabs SPECT technology in small animals has sparked enthusiasm amongst clinicians and brain researchers worldwide. In this Stage 1 SME Instrument, MILabs will investigate the commercial feasibility of this exciting technology by (i) identifying and assessing those indications to which the clinical utility yield the best initial market value, (ii) developing a sound clinical validation strategy and (iii) defining the route-to-market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRAINSPECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRAINSPECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More